• Report Adverse Reaction
  • Approved fees Schedules
  • Products Recall And Alert
  • For Stakeholders
  • Submit a Complaint
  • FAQs
  • Submit Advert Application
  • Submit Advert Application
  • Consumer Education
  • General Publications

    Click Topic to Download File
    FOOD AND DRUGS AUTHORITY PUBLIC ASSESSMENT REPORT 242
    FOOD AND DRUGS AUTHORITY PUBLIC ASSESSMENT REPORT - IUMO - 241
    Product Recall Database.pdf
    GBT440-038 - FDA_CT_PAR_243.pdf
    ROBOCOW - FDA_CT_PAR_245.pdf
    VX21-147-301 - KBTH - FDA_CT-PAR-244.pdf
    VX21-147-301_Bank Hospital - FDA_CT_PAR_246.pdf
    INTS - FDA_CT_PAR_247.pdf
    LIST OF APPROVED ADVERT 2024-DRUGS- April
    PAR-AFH0040-23-CANESTEN SOFT GEL OVULES
    Annex II PIL-PREBAXE 150mg CAPSULES
    Annex III SmPC-PREBAXE 150mg CAPSULES
    PAR-AFH0156-22-PREBAXE 50mg CAPSULES
    Annex II PIL-PREBAXE 150mg CAPSULES
    Annex III SmPC-PREBAXE 150mg CAPSULES
    PAR-AFH0157-22-PREBAXE 75mg CAPSULES
    Annex I Pack shots-PREBAXE 150mg CAPSULES.pdf
    Annex II PIL-PREBAXE 150mg CAPSULES
    Annex III SmPC-PREBAXE 150mg CAPSULES
    PAR-AFH0158-22-PREBAXE 150mg CAPSULES
    PAR-AFH0183-22-UROFAST-GRANULES FOR ORAL SOLUTION
    Annex I Pack shots
    SUMMARY OF RISK MANAGEMENT PLAN FOR COVERSYL PLUS (Perindopril and Indapamide)- VERSION 3.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR SERDERAX (Perindopril and Indapamide)- VERSION 3.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR CYCLOSERINE- VERSION 1.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR URISPAS (FLAVOXATE HYDROCHLORIDE)- VERSION 2.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR COVERAM (PERINDOPRIL ARGININE/AMLODIPINE)- VERSION 3.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR SERPERAM (PERINDOPRIL ARGININE/AMLODIPINE)- VERSION 3.0
    CANESTEN SOFT GEL OVULES Annex III-SmPC
    CANESTEN SOFT GEL OVULES Annex II-PIL.pdf
    Annex I Pack Shot
    LIST OF APPROVED ADVERT 2024 - DRUGS- 1ST - 31ST MARCH
    SUMMARY OF RISK MANAGEMENT PLAN FOR NIZACARD (RANOLAZINE) - VERSION 1.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR AXABAN-DENK (APIXABAN) - VERSION 1.0
    SUMMARY OF RISK MANAGEMENT PLAN FOR SYNJARDY (EMPAGLIFLOZIN + METFORMIN)- VERSION 12
    LIST OF APPROVED LOCALLY MANUFACTURED BLEACH
    SUMMARY OF RISK MANAGEMENT PLAN FOR SERINXAM (PERINDOPRIL ARGININE/INDAPAMIDE/AMLODIPINE)
    SUMMARY OF RISK MANAGEMENT PLAN FOR ULTRAVIST (IOPROMIDE)
    LIST OF APPROVED ADVERT 20th JAN to 29th February 2024
    NEW FDA FEES AND CHARGES
    QUALIFIED PERSONS FOR PHARMACOVIGILANCE WITH GOOD STANDING - FEBRUARY 2024
    LIST OF MARKET AUTHORIZATION HOLDERS QUALIFIED PERSONS FOR PHARMACOVIGILANCE WITH GOOD STANDING FEB 2024
    CLINICAL TRIAL REGISTRY
    NOTICE OF VACANCY - TAC
    LABEL VARIATIONS FROM MARKET AUTHORIZATION HOLDERS
    FDA GUIDELINE ON IDENTIFICATION AND DATA CAPTURE FOR PHARMACEUTICAL TRACEABILITY
    UPDATE NO. 11 ON THE SAFETY MONITORING OF THE MALARIA VACCINE
    LIST OF APPROVED ADVERTS (DRUGS, COSMETICS, MEDICAL DEVICES, AND HOUSEHOLD CHEMICALS)
    PROPOSAL FOR THE DEVELOPMENT OF REGIONAL CENTRE OF REGULATORY EXCELLENCE (RCORE) MANUAL FOR VACCINES AND BIOLOGICAL PRODUCTS
    PROPOSAL FOR THE DEVELOPMENT OF PHARAMCOVIGILANCE REGIONAL CENTRE OF REGULATORY EXCELLENCE (RCORE) MANUAL
    QUALIFIED PERSONS FOR PHARMACOVIGILANCE (QPPV) OCTOBER 2023 LIST
    SUSPECTED THERAPEUTIC INEFFECTIVENESS OF BUPIVACAINE HYDROCHLORIDE INJECTION.pdf
    LIST OF LICENSED BLOOD FACILITIES IN GHANA
    LIST OF APPROVED BLEACHES
    LIST OF APPROVED ADVERTS 2023 (DRUGS, COSMETICS, MEDICAL DEVICES AND HOUSEHOLD CHEMICALS)
    ALERT- UNREGISTERED GALVUS MET 50mg-1000mg TABLETS ON THE GHANIAN MARKET
    UPDATE NO. 10 ON THE SAFETY MONITORING OF THE MALARIA VACCINE
    QUALITY MANAGEMENT SYSTEMS OF THE FOOD AND DRUGS AUTHORITY
    2023 VIRTUAL ANNUAL GOOD CLINICAL PRACTICE TRAINING
    JOINT STATEMENT BY THE FOOD AND DRUGS AUTHORITY AND GHANA HEALTH SERVICE ON WORLD BREASTFEEDING WEEK CELEBRATION 2023
    FDA Holds Maiden Stakeholder Meeting on Regulatory Activities and 2022 Performance
    LIST OF APPROVED ADVERTISEMENTS (DRUGS) - JANUARY TO JUNE 2023
    ARTICLE - WORLD NO TOBACCO DAY 2023
    SUMMARY REPORT R21 MALARIA VACCINE (RECOMBINANT ADJUVANTED)
    Terms of Reference to recruit a consultant for the CEPI LASSA ML enhancement 2d
    HARMFUL EFFECTS ON TOBACCO
    WORLD NO TOBACCO DAY 2023 E-FLYERS
    PUBLIC NOTICE
    GUIDELINES FOR THE PUBLICATION OF GMP INSPECTION REPORT
    FAQs ON R21 MALARIA VACCINE
    HILLS PHARMACEUTICALS LTD - IMMEDIATE PRODUCT RECALL
    LIST OF APPROVED ADVERTS (JANUARY TO DECEMBER 2022)
    Qualified Persons for Pharmacovigilance with Good Standing
    HUMAN RESOURCE POLICY FRAMEWORK & MANUAL, Ghana Public Services
    EFFECTS OF THE USE OF POLYETHYLENE FOR PACKAGING FANTE KENKEY
    13TH TRAINING PROGRAMME FOR QUALIFIED PERSONS FOR PHARMACOVIGILANCE
    EXECUTIVE INSTRUMENT 167
    EXECUTIVE INSTRUMENT 168
    RESTRICTED LIST OF PHARMACEUTICAL PRODUCTS
    ADVANCEMENT OF TOBACCO CONTROL IN GHANA BARRIERS & OPPORTUNITIES - A BRIEF SITUATION REPORT
    FAPAR - PUBLIC ASSESSMENT REPORT TABLE TO APPLICANTS
    NOTICE TO IMPORTERS AND MANUFACTURERS OF PHARMACEUTICAL, FOOD AND COSMETIC PRODUCTS
    National Haemovigilance Framework for Ghana
    Guidelines For Haemovigilance in Ghana
    MALARIA VACCINE IMPLEMENTATION PROGRAMME JULY UPDATE
    MADE-IN-GHANA POLICY BRIEF
    LIST OF LICENSED ANIMAL PRODUCTS COLD STORAGE FACILITIES
    LIST OF LICENSED FOOD STORAGE FACILTIES
    LIST OF LICENSED LOCAL FEED WAREHOUSE FACILITIES
    LIST OF LICENSED MDCHC STORAGE FACILTIES
    LIST OF LICENSED MEAT SHOP FACILITIES
    LIST OF LICENSED PHARMACEUTICALS STORAGE FACILITIES
    LIST OF LICENSED FOREIGN PHARMACEUTICAL MANUFACTURING FACILITIES
    LIST OF LICENSED FOREIGN MEDICAL DEVICES COSMETICS AND HOUSEHOLD CHEMICAL SUBSTANCES MANUFACTURING FACILITIES
    LIST OF LICENSED FOREIGN FOOD MANUFACTURING FACILITIES
    LIST OF LICENSED LOCAL AGRO PRODUCTS PACKHOUSES
    LIST OF LICENSED LOCAL ANIMAL FEED MANUFACTURING FACILITIES
    LIST OF LICENSED LOCAL ANIMAL PRODUCTS PROCESSING FACILITIES
    LIST OF LICENSED LOCAL FOOD MANUFACTURING FACILITIES
    LIST OF LICENSED LOCAL MEDICAL DEVICES COSMETICS AND HOUSEHOLD CHEMICAL SUBSTANCES (MDCHC) MANUFACTURING FACILITIES
    APPLICATION FORM FOR 2022 VIRTUAL ANNUAL GOOD CLINICAL PRACTICE TRAINING
    LIST OF PCR CENTERS IN GHANA
    NATIONAL FOOD SAFETY POLICY
    NATIONAL FOOD SAFETY EMERGENCY RESPONSE PLAN(FOSERP)
    12TH TRAINING PROGRAMME FOR QUALIFIED PERSONS FOR PHARMACOVIGILANCE
    LIST OF RECOMMENDED PHARMACOVIGILANCE COURSES FOR QPPV 2022
    FDA CLIENT SERVICE DELIVERY CHARTER
    THE USE AND ABUSE OF NAPHTHALENE BALLS IN GHANA
    SAFETY MONITORING OF MALARIA VACCINE (7TH UPDATE)
    LIST OF FDA REGISTERED COVID-19 ANTIGEN RAPID DIAGNOSTIC TEST KITS
    FDA's EMERGENCY USE AUTHORISATION FOR MEDICAL PRODUCTS
    COVID-19 VACCINES GRANTED EMERGENCY USE AUTHORIZATION (EUA) BY THE GHANA FOOD AND DRUGS AUTHORITY (FDA)
    MARKET AUHTORISATION HOLDERS COMPLIANT WITH SECTION 125 OF THE PUBLIC HEALTH ACT, ACT 851
    LIST OF QUALIFIED PERSONS FOR PHARMACOVIGILANCE
    3RD EXPRESSION OF INTEREST (EOI) FOR MEDICAL PRODUCTS FOR THE ECOWAS JOINT ASSESSMENT PROCEDURE UNDER THE WEST AFRICA MEDICINES REGULATORY HARMONIZATION (WA-MRH)
    11TH TRAINING PROGRAMME FOR QUALIFIED PERSONS FOR PHARMACOVIGILANCE
    LIST OF COVID-19 APPROVED MEDICAL DEVICES FOR EMERGENCY USE
    COVID-19 VACCINE SAFETY MONITORING STRATEGY
    JOINT COVID-19 VACCINE SAFETY REVIEW COMMITTEE
    FREQUENTLY ASKED QUESTIONS ON COVID-19 VACCINE SAFETY (Ghana)
    GUIDELINES FOR EMERGENCY USE AUTHORIZATION OF MEDICAL PRODUCTS IN GHANA
    WEARING OF DOUBLE FACE MASKS FOR COVID-19 PREVENTION IN THE WAKE OF EMERGING NEW SARS-COV-2 VARIANTS - THE FDA's PERSPECTIVE
    SUMMARY ON BERC-AFRICA PROJECT FUNDED BY EUROPEAN AND DEVELOPMENT COUNTRIES CLINICAL TRIALS PARTNERSHIP(EDCTP)
    PICTORIAL HEALTH WARNING (PHWs) IMPLEMENTATION ON TOBACCO AND TOBACCO PRODUCTS PACKAGES
    LIST OF MARKETING AUTHORISATION HOLDERS WHO HAVE UNDERGONE GOOD PHARMACOVIGILVANCE PRACTICE INSPECTION
    FOURTH UPDATE ON THE SAFETY MONITORING OF MEDICINES FOR THE TREATMENT OF COVID-19 FROM 1ST APRIL TO 31ST AUGUST 2020
    SAFETY MONITORING OF THE MALARIA VACCINE (UPDATE NO.4)
    GUIDELINES FOR THE RETAIL AND WHOLESALE OF CONTROLLED SUBSTANCES
    FOOD AND DRUGS AUTHORITY DRAFT GUIDELINES COMMENTS SHEET
    THE ROLE AND PARTNERSHIP OF THE FOOD AND DRUGS AUTHORITY (FDA) WITH THE AFRICAN CONTINENTAL FREE TRADE AREA (AfCFTA)
    CODE OF PRACTICE FOR SALES
    FDA PRIVACY POLICY FOR INDIVIDUAL CASE SAFETY REPORTS
    WAIVERS FOR CURRENT GOOD MANUFACTURING PRACTICES (cGMP) INSPECTIONS FOR PHARMACEUTICAL PRODUCTS, INNOVATOR VACCINES AND BIOLOGICAL PRODUCTS
    LIST OF CONTROLLED SUBSTANCES REGULATED BY FOOD AND DRUGS AUTHORITY
    FDA RELIANCE POLICY
    MALARIA VACCINE IMPLEMENTATION PROGRAM UPDATE APRIL 2020

    THE FDA MISSION

    The FDA exist to ensure the safety, quality and efficacy of human and veterinary drugs, food, biological products, cosmetics, medical devices, household chemical substances and clinical trials, and the control of tobacco products through the enforcement of relevant standards to protect public health.

  • Discover More
  • Subscription Management Centre

    Connect & Get Interactive

  • Top